AstraZeneca's Imfinzi (durvalumab) plus chemotherapy, has gained CHMP recommendation for approval in the EU to treat NSCLC.

AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...

member of the AEGEAN Steering Committee and investigator in the trial, said: "Adding perioperative durvalumab to neoadjuvant chemotherapy significantly improved outcomes for patients with ...

The study met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement in EFS with the durvalumab regimen vs the placebo regimen. Topline results were ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...

The Cambridge, England-based pharmaceuticals firm said Imfinzi, or durvalumab, in combination ... and was based on results from the Aegean phase three trial. In the trial, the drug showed a ...

Recommendation based on AEGEAN Phase III trial results which showed Imfinzi reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone AstraZeneca’s Imfinzi ...